1167 — Jacobio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$3.91bn
- HK$2.13bn
- CNY53.53m
Brief: Jacobio Pharmaceuticals Says KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designations
Brief: Jacobio Pharmaceuticals Announces Collaboration With Merck
Brief: Jacobio Pharmaceuticals Received Cde Approval For Phase Ii Pivotal Study Of Kras G12c Inhibitor Jab-21822
Brief: Jacobio Completes First Patient Dosage Of Cd73 Mab Jab-Bx102 In China
Brief: Jacobio Pharmaceuticals - HY Loss Rmb127.8 Million Versus Loss Of Rmb136.6 Million
Brief: Jacobio Will Present Phase I Clinical Data Of Kras G12c Inhibitor Jab-21822 At The 2022 Asco Annual Meeting
Brief: Jacobio Pharmaceuticals Says It Got IND Approval Of Cd73 Mab Jab-Bx102 From Center For Drug Evaluation In China
Brief: Jacobio Pharmaceuticals Posts FY Loss Attributable Of RMB301.2 Million
Brief: Jacobio Pharmaceuticals Gets Investigational New Drug Approval For Jab-2485 In U.S.
Brief: Jacobio Pharmaceuticals Says It Received IND Approval Of Drug From CDE Of PRC
Brief: Jacobio Pharmaceuticals Says Got IND Approval Of CD73 MAB JAB-BX102 From U.S. FDA
Brief: Hebecell Raises $53 Million In Series A Financing
Brief: Jacobio Pharmaceuticals Entered Share Purchase Agreement With Hebecell Holding
Brief: Jacobio Pharmaceuticals Group Receives China CDE Investigational New Drug- Clearance For KRAS G12C Inhibitor
Brief: Jacobio Pharmaceuticals Group Receives U.S. FDA Investigational New Drug Clearance
Brief: Jacobio Pharmaceuticals Group Says FY Loss RMB1,513.7 Mln
Brief: Jacobio Pharm Announces On Partial Exercise Of Over-Allotment Option
China's Jacobio Pharmaceuticals jumps in Hong Kong debut